Go Pro
→ How to get a stake in Anthropic — before the IPO (From Weiss Ratings) (Ad)tc pixel Free CMND Stock Alerts

Clearmind Medicine (CMND) Competitors

Clearmind Medicine logo
$0.85 +0.07 (+8.81%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$0.85 0.00 (-0.35%)
As of 08:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CMND vs. RDHL, SXTP, XRTX, ORGS, and SILO

Should you buy Clearmind Medicine stock or one of its competitors? Clearmind Medicine's main competitors and comparable companies include Redhill Biopharma (RDHL), 60 Degrees Pharmaceuticals (SXTP), XORTX Therapeutics (XRTX), Orgenesis (ORGS), and Silo Pharma (SILO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Clearmind Medicine compare to Redhill Biopharma?

Clearmind Medicine (NASDAQ:CMND) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clearmind Medicine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Redhill Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Redhill Biopharma has higher revenue and earnings than Clearmind Medicine. Clearmind Medicine is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clearmind MedicineN/AN/A-$3.86M-$40.55N/A
Redhill Biopharma$290K11.39-$430K$900.000.00

Clearmind Medicine has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 4.96, meaning that its stock price is 396% more volatile than the broader market.

96.1% of Clearmind Medicine shares are held by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are held by institutional investors. 6.8% of Redhill Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Clearmind Medicine had 3 more articles in the media than Redhill Biopharma. MarketBeat recorded 3 mentions for Clearmind Medicine and 0 mentions for Redhill Biopharma. Clearmind Medicine's average media sentiment score of 0.67 beat Redhill Biopharma's score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the media.

Company Overall Sentiment
Clearmind Medicine Positive
Redhill Biopharma Neutral

Redhill Biopharma's return on equity of 0.00% beat Clearmind Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Clearmind MedicineN/A -88.53% -61.62%
Redhill Biopharma N/A N/A N/A

Summary

Redhill Biopharma beats Clearmind Medicine on 9 of the 12 factors compared between the two stocks.

How does Clearmind Medicine compare to 60 Degrees Pharmaceuticals?

Clearmind Medicine (NASDAQ:CMND) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

60 Degrees Pharmaceuticals has a consensus target price of $13.85, indicating a potential upside of 1,093.97%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Clearmind Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clearmind Medicine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
60 Degrees Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Clearmind Medicine had 1 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 3 mentions for Clearmind Medicine and 2 mentions for 60 Degrees Pharmaceuticals. Clearmind Medicine's average media sentiment score of 0.67 beat 60 Degrees Pharmaceuticals' score of 0.42 indicating that Clearmind Medicine is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Clearmind Medicine
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
60 Degrees Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Clearmind Medicine has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.54, indicating that its share price is 154% more volatile than the broader market.

Clearmind Medicine has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -650.21%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Clearmind Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Clearmind MedicineN/A -88.53% -61.62%
60 Degrees Pharmaceuticals -650.21%N/A -136.81%

Clearmind Medicine has higher earnings, but lower revenue than 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clearmind MedicineN/AN/A-$3.86M-$40.55N/A
60 Degrees Pharmaceuticals$1.41M2.90-$7.36M-$4.82N/A

96.1% of Clearmind Medicine shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

60 Degrees Pharmaceuticals beats Clearmind Medicine on 8 of the 15 factors compared between the two stocks.

How does Clearmind Medicine compare to XORTX Therapeutics?

XORTX Therapeutics (NASDAQ:XRTX) and Clearmind Medicine (NASDAQ:CMND) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

0.2% of XORTX Therapeutics shares are owned by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are owned by institutional investors. 6.9% of XORTX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

XORTX Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the broader market. Comparatively, Clearmind Medicine has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

Clearmind Medicine's return on equity of -88.53% beat XORTX Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
XORTX TherapeuticsN/A -137.85% -108.16%
Clearmind Medicine N/A -88.53%-61.62%

XORTX Therapeutics is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XORTX TherapeuticsN/AN/A-$2.66M-$2.73N/A
Clearmind MedicineN/AN/A-$3.86M-$40.55N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XORTX Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Clearmind Medicine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, XORTX Therapeutics had 1 more articles in the media than Clearmind Medicine. MarketBeat recorded 4 mentions for XORTX Therapeutics and 3 mentions for Clearmind Medicine. Clearmind Medicine's average media sentiment score of 0.67 beat XORTX Therapeutics' score of 0.15 indicating that Clearmind Medicine is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
XORTX Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Clearmind Medicine
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Clearmind Medicine beats XORTX Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Clearmind Medicine compare to Orgenesis?

Orgenesis (NASDAQ:ORGS) and Clearmind Medicine (NASDAQ:CMND) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

Orgenesis has a beta of 3.16, meaning that its stock price is 216% more volatile than the broader market. Comparatively, Clearmind Medicine has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

In the previous week, Clearmind Medicine had 3 more articles in the media than Orgenesis. MarketBeat recorded 3 mentions for Clearmind Medicine and 0 mentions for Orgenesis. Clearmind Medicine's average media sentiment score of 0.67 beat Orgenesis' score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the news media.

Company Overall Sentiment
Orgenesis Neutral
Clearmind Medicine Positive

Clearmind Medicine has lower revenue, but higher earnings than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Orgenesis$662K4.53-$55.36M-$11.51N/A
Clearmind MedicineN/AN/A-$3.86M-$40.55N/A

Clearmind Medicine has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Clearmind Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Orgenesis-3,827.81% N/A -130.18%
Clearmind Medicine N/A -88.53%-61.62%

22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are owned by institutional investors. 1.9% of Orgenesis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Clearmind Medicine beats Orgenesis on 7 of the 12 factors compared between the two stocks.

How does Clearmind Medicine compare to Silo Pharma?

Silo Pharma (NASDAQ:SILO) and Clearmind Medicine (NASDAQ:CMND) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silo Pharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Clearmind Medicine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Clearmind Medicine has a net margin of 0.00% compared to Silo Pharma's net margin of -6,726.39%. Silo Pharma's return on equity of -81.75% beat Clearmind Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Silo Pharma-6,726.39% -81.75% -66.35%
Clearmind Medicine N/A -88.53%-61.62%

Silo Pharma has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market. Comparatively, Clearmind Medicine has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

5.6% of Silo Pharma shares are owned by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are owned by institutional investors. 3.6% of Silo Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Clearmind Medicine has lower revenue, but higher earnings than Silo Pharma. Silo Pharma is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silo Pharma$70K40.20-$4.23M-$4.36N/A
Clearmind MedicineN/AN/A-$3.86M-$40.55N/A

In the previous week, Silo Pharma had 1 more articles in the media than Clearmind Medicine. MarketBeat recorded 4 mentions for Silo Pharma and 3 mentions for Clearmind Medicine. Clearmind Medicine's average media sentiment score of 0.67 beat Silo Pharma's score of 0.50 indicating that Clearmind Medicine is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Silo Pharma
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Clearmind Medicine
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Clearmind Medicine beats Silo Pharma on 7 of the 13 factors compared between the two stocks.

Get Clearmind Medicine News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMND and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMND vs. The Competition

Export
MetricClearmind MedicinePharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$800K$12.61B$7.31B$13.28B
Dividend YieldN/A2.63%2.52%12.57%
P/E Ratio-0.02792.28274.1025.70
Price / SalesN/A857.09672.6190.85
Price / CashN/A88.6477.8052.76
Price / Book0.0710.5710.486.32
Net Income-$3.86M$2.81B$3.49B$359.73M
7 Day Performance-0.93%-0.17%-0.68%0.17%
1 Month Performance-49.40%-1.39%-3.18%-3.27%
1 Year Performance-99.79%2.83%15.13%5.58%

Clearmind Medicine Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMND
Clearmind Medicine
1.5658 of 5 stars		$0.85
+8.8%		N/A-99.8%$800KN/AN/A4
RDHL
Redhill Biopharma
1.1431 of 5 stars		$0.58
+4.9%		N/A-66.5%$3.58M$290K0.00210
SXTP
60 Degrees Pharmaceuticals
1.8902 of 5 stars		$0.94
+1.6%		$13.85
+1,375.0%		-79.1%$3.31M$1.41MN/A3
XRTX
XORTX Therapeutics
0.8125 of 5 stars		$1.77
-0.8%		N/A-60.9%$3.22MN/AN/AN/A
ORGS
Orgenesis
N/A$0.59
flat		N/A+182.9%$3.05M$662KN/A150

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CMND) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
Everyone remembers January's silver spike. Then what?
Silver is up more than 50 percent over the past year, yet interest has faded since its January record. The ...
i2i Marketing Group, LLC | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
While SpaceX Gets the Spotlight, FJET Is Building What Comes Next!
Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...
Trading Wire | Sponsoredtc pixel
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
They're shrinking your dollars every single month
Since 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...
American Alternative | Sponsoredtc pixel
Why I believe the AI market will split in Q4
Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...
The Oxford Club | Sponsoredtc pixel
Arizona Gold Explorer Nears First-Ever Resource Estimate
A little-known Arizona gold explorer just hit 66.2 metres grading 6.57 g/t gold, including 20.7 metres at 18.2...
Wall Street Logic | Sponsoredtc pixel
Congress Passes Landmark Digital Asset Law Wall Street Is Watching
The House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...
Awesomely | Sponsoredtc pixel